Hu X - Search Results

1

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Yin Y, Shi Y, Pan Y, Wang Y, Xie W, Yan M, Liu Y, Yan P, Wu F, Zhu X, Zou J; DAWNA-1 Study Consortium. Xu B, et al. Among authors: hu x. Nat Med. 2021 Nov;27(11):1904-1909. doi: 10.1038/s41591-021-01562-9. Epub 2021 Nov 4. Nat Med. 2021. PMID: 34737452 Clinical Trial.

2

XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population.

Wang Z, Xu B, Lin D, Tan W, Leaw S, Hong X, Hu X. Wang Z, et al. Among authors: hu x. Lung Cancer. 2008 Oct;62(1):99-104. doi: 10.1016/j.lungcan.2008.02.019. Epub 2008 Apr 9. Lung Cancer. 2008. PMID: 18400332

3

Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.

Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, Li T, Ni C, Wu Z, Shao Z, Hu X. Fan M, et al. Among authors: hu x. Breast Cancer Res Treat. 2014 Jan;143(1):141-51. doi: 10.1007/s10549-013-2793-6. Epub 2013 Dec 1. Breast Cancer Res Treat. 2014. PMID: 24292957 Clinical Trial.

4

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, Fan M, Li J, Wang B, Wang Z, Zhang Q, Sun S, Liao C. Hu X, et al. Int J Cancer. 2014 Oct 15;135(8):1961-9. doi: 10.1002/ijc.28829. Epub 2014 Mar 20. Int J Cancer. 2014. PMID: 24604288 Free article. Clinical Trial.

5

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.

Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, Wang B, Chen X, Yu H. Hu X, et al. Among authors: hu w. BMC Cancer. 2014 Nov 7;14:820. doi: 10.1186/1471-2407-14-820. BMC Cancer. 2014. PMID: 25376790 Free PMC article. Clinical Trial.

6

A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.

Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z. Zhang J, et al. Among authors: hu x. Cancer Biol Ther. 2015;16(2):225-32. doi: 10.4161/15384047.2014.986973. Cancer Biol Ther. 2015. PMID: 25648299 Free PMC article. Clinical Trial.

7

Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.

Lv F, Cao J, Liu Z, Wang Z, Zhang J, Zhang S, Wang L, Zhao X, Shao Z, Wang B, Hu X. Lv F, et al. Among authors: hu x. PLoS One. 2015 Mar 13;10(3):e0118607. doi: 10.1371/journal.pone.0118607. eCollection 2015. PLoS One. 2015. PMID: 25768439 Free PMC article. Clinical Trial.

8

National consensus in China on diagnosis and treatment of patients with advanced breast cancer.

Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J, Shen K, Sun T, Teng Y, Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P, Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S. Xu B, et al. Among authors: hu x. Ann Transl Med. 2015 Oct;3(17):242. doi: 10.3978/j.issn.2305-5839.2015.09.47. Ann Transl Med. 2015. PMID: 26605288 Free PMC article. Review.

9

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.

Xu B, Hu X, Zheng H, Wang X, Zhang Q, Cui S, Liu D, Liao N, Luo R, Sun Q, Yu S. Xu B, et al. Among authors: hu x. Oncotarget. 2016 Aug 2;7(31):50643-50655. doi: 10.18632/oncotarget.9331. Oncotarget. 2016. PMID: 27276706 Free PMC article.

10

Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.

Lin Y, Wu Z, Zhang J, Hu X, Wang Z, Wang B, Cao J, Wang L. Lin Y, et al. Among authors: hu x. Tumour Biol. 2017 Jun;39(6):1010428317711033. doi: 10.1177/1010428317711033. Tumour Biol. 2017. PMID: 28639910 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32,316 results

Search Page